Quanterix Q3 net loss $35.1M; takes $20.6M in impairment and restructuring charges

Quanterix Corp

2022-Q3 EPS reported -$2.12 revenue$79,698,000

Revenue $26.6M flat YoY excluding RADx, up 13% QoQ; pro-forma gross margin 35.0% (down 1470 bps YoY, up 670 bps QoQ).
Net loss $35.1M ($0.95/share) vs $15.7M loss a year ago; operating loss $36.6M.
Recorded $8.2M goodwill impairment, $8.7M long-lived asset impairment, $3.4M restructuring costs in Q3.
Business highlights: BioHermes pTau-181 trial nearing completion for FDA clearance; ADDF-funded Alzheimer's plasma test on track.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quanterix Corp reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Quanterix Corporation (“Quanterix”) issued a press release announcing its financial results for the third quarter ended September 30, 2022 (the “Earnings Release”).

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-115930

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.